Veridex, Mass Gen work on circulating tumor cell technology
Johnson & Johnson’s Veridex LLC (cancer diagnostics) and Massachusetts General Hospital will together develop and market a next-generation circulating tumor cell (CTC) technology to capture, count, and characterize tumor cells located in a patient’s blood. The five-year deal is worth $30mm, consisting of a technology license fee and milestones, plus royalties.
- In Vitro Diagnostics
In Vitro Diagnostics
- Chemistry, Immunoassay
- Drug Discovery Tools
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.